drug approvals

FDA Layoffs and Voucher Program Expiration Cast Shadow Over Rare Disease Drug Development

The FDA's pediatric priority review voucher program expired in December 2024, causing uncertainty for drug developers. Combined with FDA layoffs, this creates an investment risk in rare pediatric drug development. Smaller companies face significant challenges, and while reauthorization is expected before 2026, investor concerns have already inflated the voucher market's value.